These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1038 related articles for article (PubMed ID: 19826130)

  • 1. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.
    Harousseau JL; Avet-Loiseau H; Attal M; Charbonnel C; Garban F; Hulin C; Michallet M; Facon T; Garderet L; Marit G; Ketterer N; Lamy T; Voillat L; Guilhot F; Doyen C; Mathiot C; Moreau P
    J Clin Oncol; 2009 Dec; 27(34):5720-6. PubMed ID: 19826130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival.
    Lahuerta JJ; Mateos MV; Martínez-López J; Rosiñol L; Sureda A; de la Rubia J; García-Laraña J; Martínez-Martínez R; Hernández-García MT; Carrera D; Besalduch J; de Arriba F; Ribera JM; Escoda L; Hernández-Ruiz B; García-Frade J; Rivas-González C; Alegre A; Bladé J; San Miguel JF
    J Clin Oncol; 2008 Dec; 26(35):5775-82. PubMed ID: 19001321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
    Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S
    Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
    Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J;
    Cancer; 2008 Jan; 112(1):129-35. PubMed ID: 17973267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission.
    Papajik T; Raida L; Faber E; Vondrakova J; Prochazka V; Kubova Z; Skoumalova I; Jarosova M; M LK; Paucek B; Myslivecek M; Neoral C; Oral I; Jarkovsky J; Dusek L; Indrak K
    Neoplasma; 2008; 55(3):215-21. PubMed ID: 18348654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs.
    Martino M; Postorino M; Gallo GA; Messina G; Neri S; Piro E; Gentile M; Moscato T; Monteleone R; Fedele R; Mazzone C; Console G; Penna G; Alati C; Vincelli ID; Irrera G; Musolino C; Ronco F; Molica S; Morabito F
    Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):148-54. PubMed ID: 24417912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma.
    Cavo M; Di Raimondo F; Zamagni E; Patriarca F; Tacchetti P; Casulli AF; Volpe S; Perrone G; Ledda A; Ceccolini M; Califano C; Bigazzi C; Offidani M; Stefani P; Ballerini F; Fiacchini M; de Vivo A; Brioli A; Tosi P; Baccarani M
    J Clin Oncol; 2009 Oct; 27(30):5001-7. PubMed ID: 19720903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.
    Inamoto Y; Kurahashi S; Imahashi N; Fukushima N; Adachi T; Kinoshita T; Tsushita K; Miyamura K; Naoe T; Sugiura I
    Am J Hematol; 2009 May; 84(5):283-6. PubMed ID: 19338045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma.
    Lokhorst HM; Sonneveld P; Cornelissen JJ; Joosten P; van Marwijk Kooy M; Meinema J; Nieuwenhuis HK; van Oers MH; Richel DJ; Segeren CN; Veth G; Verdonck LF; Wijermans PW
    Bone Marrow Transplant; 1999 Feb; 23(4):317-22. PubMed ID: 10100574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study.
    Cavo M; Tosi P; Zamagni E; Cellini C; Tacchetti P; Patriarca F; Di Raimondo F; Volpe E; Ronconi S; Cangini D; Narni F; Carubelli A; Masini L; Catalano L; Fiacchini M; de Vivo A; Gozzetti A; Lazzaro A; Tura S; Baccarani M
    J Clin Oncol; 2007 Jun; 25(17):2434-41. PubMed ID: 17485707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
    Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F
    Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
    van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF;
    J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High dose chemotherapy and autologous stem cell transplantation in patients with multiple myeloma: the experience of a single haematological unit.
    Papanikolaou X; Maltezas D; Repousis P; Athanassopoulos A; Alexia S; Megalakaki K; Kotsopoulou M; Mitsouli-Mentzikof C
    J BUON; 2008; 13(2):193-7. PubMed ID: 18555464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival.
    Kim MK; Kim S; Lee SS; Sym SJ; Lee DH; Jang S; Park CJ; Chi HS; Huh J; Suh C
    Ann Hematol; 2007 Jun; 86(6):435-42. PubMed ID: 17256144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single versus double autologous stem-cell transplantation for multiple myeloma.
    Attal M; Harousseau JL; Facon T; Guilhot F; Doyen C; Fuzibet JG; Monconduit M; Hulin C; Caillot D; Bouabdallah R; Voillat L; Sotto JJ; Grosbois B; Bataille R;
    N Engl J Med; 2003 Dec; 349(26):2495-502. PubMed ID: 14695409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up after high-dose therapy for high-risk multiple myeloma.
    Barlogie B; Jagannath S; Naucke S; Mattox S; Bracy D; Crowley J; Tricot G; Alexanian R
    Bone Marrow Transplant; 1998 Jun; 21(11):1101-7. PubMed ID: 9645572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
    Lee CK; Barlogie B; Zangari M; Fassas A; Anaissie E; Morris C; Van Rhee F; Cottler-Fox M; Thertulien R; Muwalla F; Mazher S; Badros A; Tricot G
    Bone Marrow Transplant; 2002 Dec; 30(12):873-8. PubMed ID: 12476279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simple variables predict survival after autologous transplantation: a single centre experience in 181 multiple myeloma patients.
    Krejci M; Hajek R; Buchler T; Krivanova A; Svobodnik A; Pour L; Adam Z; Mayer J; Vorlicek J
    Neoplasma; 2007; 54(2):143-8. PubMed ID: 17319788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.